Further progress for Relievant and Intracept follows Tuesday’s major news of an agreement for Boston Scientific to acquire the company. Boston Scientific officials went into further detail on their expectations for the Relievant deal at the company’s Investor Day yesterday.
Minneapolis-based Relievant develops the Intracept intraosseous nerve ablation system for chronic pain. The minimally invasive, FDA-cleared, same-day, outpatient procedure treats chronic vertebrogenic low back pain. Intracept utilizes targeted radiofrequency energy to ablate the basivertebral nerve (BVN). This stops the nerve from transmitting pain signals to the brain. The procedure takes approximately one hour to perform.
Relievant based its simulator system for Intracept on Medability’s SimBone simulation platform. It uses radiation-free simulation technology to provide an immersive, hands-on training experience. The platform includes virtual X-ray, computed tomography (CT) imaging and navigation with a realistic lumbosacral spine model.
According to the company, the system enables a consistent and reliable learning experience with next-generation Intracept access instruments.
“We are dedicated to supporting physicians with clinical training and education to increase procedural efficiency and enable better patient outcomes,” said Tyler Binney, president and CEO of Relievant Medsystems. “The Intracept simulator system is an important innovation that will empower more physicians to provide their patients with vertebrogenic pain relief.”
